CDK1 and hepatocellular carcinoma: However, due to the complexity and heterogeneity of HCC, the therapeutic efficacy of a single CDK1 inhibitor is limited, and it usually needs to be combined with other therapies (for example, immunotherapy, targeted therapy, etc.)to achieve optimal efficacy [40].